Anteris Technologies Global Corp., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $15.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Josh Jennings has given his Buy rating due to a combination of factors that highlight Anteris Technologies Global Corp.’s strong position in advancing its clinical development program. The recent approval by the FDA for the PARADIGM PMA trial is a significant milestone, allowing Anteris to begin enrollment in the United States, which is a critical step in the regulatory process.
The design of the PARADIGM trial itself is a strategic advantage for Anteris, as it is a comprehensive, multicenter international study that compares the DurAVR valve to existing commercial TAVR devices. This trial will provide valuable data on the safety and effectiveness of the DurAVR valve across a wide range of patients, including those at high, intermediate, and low risk. The trial’s primary and secondary endpoints are well-aligned with industry standards, ensuring that the results will be robust and credible. These developments position Anteris favorably in the competitive landscape of aortic valve replacement technologies, supporting the Buy rating.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $20.00 price target.